VAXXIUM Your partner for the development of new vaccines

VAXXIUM is a consortium consisting of highly qualified experts in industry, universities and higher education. Its goal: to emphasise Belgian skills and capacity in the field of vaccinology and to develop new vaccines.

VAXXIUM is the result of a partnership between ECSOR and CEVAC, a company established on the UZ Ghent site which conducts early phase clinical trials in the field of vaccinology, a science in its own right at the frontiers of microbiology, immunology and biotechnology. The CEVAC team has led over 25 phase I and I / II trials assessing vaccine candidates that use new antigens, new administration systems and new adjuvants. In addition, the CEVAC Immunology Laboratory has conducted immunomonitoring tests for over 20 phase I and I / II clinical trials assessing vaccine candidates. ECSOR and CEVAC share a precious competitive advantage: staff of the same seniority and expertise. A first phase I clinical trial - now completed - has allowed them to confirm that their teams worked very well alongside each other. Conducted in partnership with the Austrian company Hoopika, this trial concerned a vaccine against cytomegalovirus (CMV) infection, which is potentially harmful to foetuses. It was followed by two other ongoing clinical trials: the first, again a phase I, concerns the respiratory syncytial virus (RSV), which is especially serious in young babies, whilst the second, a phase II trial, focuses on the development of a universal influenza (flu) vaccine. In the future, all this work will make it possible to respond (at least partly) to medical needs that have yet to be met: Ebola virus, dengue fever, AIDS etc. Alongside prophylactic vaccines, research is also being developed that is dedicated to therapeutic vaccines, especially for AIDS. However, we are still waiting for the results. In this context, VAXXIUM fully intends to offer its services to the innovation drivers, the start-up companies, the spin-offs created by universities and large pharmaceutical laboratories: with a stage of development that is often limited to preclinical. It is in their best interests to turn to the staff and skills of the consortium, which will be only too pleased to offer à la carte services that may be lacking in the long procedural marathon that a clinical trial represents. Plenty of future promise for VAXXIUM. Mr Jacques Bruhwyler, PhD, CEO Squarepoint – Pointcarré, Director and Associate at ECSOR © ECSOR

The services provided by the consortium are exhaustive: medical writing, data management, biostatistics, submission to ethics committees and competent health authorities, clinical monitoring, electronic case report form (eCRF), electronic patient-reported outcomes (ePRO), pharmacovigilance, clinical vaccinology centre and immunology laboratory, integrated clinical study reports and publications.

VAXXIUM Rue de la Stationstraat 78 - B-1630 Linkebeek Tel: +32 (0)2 383 04 55 Email: info@vaxxium.com http://vaxxium.com/